Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
Mar 06, 2018 21:06 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., March 06, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
Bojangles’, Inc. Reports Financial Results for its Fourth Fiscal Quarter and Fiscal Year 2017
Mar 06, 2018 21:06 pm UTC| Business
CHARLOTTE, N.C., March 06, 2018 -- Bojangles’, Inc. (Bojangles’) (NASDAQ:BOJA) today announced financial results for the 14-week fourth fiscal quarter and 53-week fiscal year ended December 31, 2017. Bojangles’ also...
Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
Mar 06, 2018 21:06 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., March 06, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March: Cowen and...
URBN Reports Record Q4 Sales and Strong Start to Spring
Mar 06, 2018 21:05 pm UTC| Business
PHILADELPHIA, March 06, 2018 -- Urban Outfitters, Inc. (NASDAQ:URBN), a leading lifestyle products and services company which operates a portfolio of global consumer brands comprised of Anthropologie, BHLDN, Free...
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 06, 2018 21:06 pm UTC| Business
WAYNE, Pa., March 06, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to...
Mar 06, 2018 21:05 pm UTC| Business
ZGN-1061 interim data suggest compound is safe and well-tolerated; no safety signals and placebo-like side effect profile ZGN-1061 interim efficacy data indicate significant A1C lowering vs. placebo at 8 weeks ...
TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference
Mar 06, 2018 21:05 pm UTC| Business
SAN DIEGO, March 06, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet...